Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1988-11-22
pubmed:abstractText
Vaccinia infection interferes with the presentation of influenza Haemagglutinin (HA) and Nucleoprotein (NP) to class I-restricted CTL. The inhibitory effect is selective for certain epitopes, and is more profound during the late phase of infection. For influenza A/NT/60/68 NP, the block is present during both early and late phases of infection, and is selective for the COOH-terminal epitope defined by peptide 366-379, having no detectable effect on the presentation of the NH2-terminal epitope 50-63. The presentation of HA is inhibited only during the late phase of vaccinia infection. For both proteins, presentation is partially (NP) or completely (HA) restored by expression of rapidly degraded protein fragments in the vaccinia infected target cell. For HA, deletion of the NH2-terminal signal sequence completely overcomes the block. For NP, either a large NH2-terminal deletion or the construction of a rapidly degraded ubiquitin-NP fusion protein partially restores presentation. These results illustrate the relationship between degradation of viral proteins in the cytoplasm of an infected cell and recognition of epitopes at the cell surface by class I-restricted T cells.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-1078719, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-16073430, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2411422, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2420472, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2437457, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2438367, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2442285, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2443447, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2836548, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-2989795, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3003914, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3010244, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3018930, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-303568, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3257585, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3310381, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3491325, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3491326, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3493144, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3501071, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3532120, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3838265, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3928633, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-3939316, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6157838, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6206156, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6206181, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6278431, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6313808, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6321770, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6327060, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-6332992, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-7144911, http://linkedlifedata.com/resource/pubmed/commentcorrection/2459295-802513
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0022-1007
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
168
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1211-24
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:2459295-Animals, pubmed-meshheading:2459295-Cells, Cultured, pubmed-meshheading:2459295-Epitopes, pubmed-meshheading:2459295-Female, pubmed-meshheading:2459295-Genetic Vectors, pubmed-meshheading:2459295-Hemagglutinins, Viral, pubmed-meshheading:2459295-Histocompatibility Antigens Class I, pubmed-meshheading:2459295-Mice, pubmed-meshheading:2459295-Mice, Inbred C57BL, pubmed-meshheading:2459295-Mice, Inbred CBA, pubmed-meshheading:2459295-Nucleoproteins, pubmed-meshheading:2459295-Orthomyxoviridae, pubmed-meshheading:2459295-Peptide Fragments, pubmed-meshheading:2459295-Precipitin Tests, pubmed-meshheading:2459295-Promoter Regions, Genetic, pubmed-meshheading:2459295-Protein Sorting Signals, pubmed-meshheading:2459295-Recombinant Fusion Proteins, pubmed-meshheading:2459295-Recombinant Proteins, pubmed-meshheading:2459295-T-Lymphocytes, Cytotoxic, pubmed-meshheading:2459295-Vaccinia virus
pubmed:year
1988
pubmed:articleTitle
Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.
pubmed:affiliation
Institute for Molecular Medicine, John Radcliffe Hospital, Headington, Oxford.
pubmed:publicationType
Journal Article
More...